MKNK1 is a YB-1 target gene responsible for imparting trastuzumab resistance and can be blocked by RSK inhibition (Q39411394)

11 September 2017

MKNK1 is a YB-1 target gene responsible for imparting trastuzumab resistance and can be blocked by RSK inhibition (English)

1 reference

11 September 2017

1 reference

7

G B Mills

1 reference

11 September 2017

A Astanehe

1

1 reference

11 September 2017

M R Finkbeiner

2

1 reference

11 September 2017

M Krzywinski

3

1 reference

11 September 2017

A Fotovati

4

1 reference

11 September 2017

J Dhillon

5

1 reference

11 September 2017

I M Berquin

6

1 reference

11 September 2017

M A Marra

8

1 reference

11 September 2017

S E Dunn

9

1 reference

11 September 2017

language of work or name

English

0 references

publication date

16 January 2012

1 reference

11 September 2017

1 reference

11 September 2017

31

1 reference

11 September 2017

41

1 reference

11 September 2017

4434-4446

1 reference

https://scigraph.springernature.com/pub.10.1038/onc.2011.617

11 September 2017

0 references

cites work

The transcriptional induction of PIK3CA in tumor cells is dependent on the oncoprotein Y-box binding protein-1.

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.617

The selectivity of protein kinase inhibitors: a further update

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.617

Nuclear localization and increased levels of transcription factor YB-1 in primary human breast cancers are associated with intrinsic MDR1 gene expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.617

A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.617

Phosphorylation of eIF4E by MNKs supports protein synthesis, cell cycle progression and proliferation in prostate cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.617

The PSF.p54nrb complex is a novel Mnk substrate that binds the mRNA for tumor necrosis factor alpha

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.617

Humanization of an anti-p185HER2 antibody for human cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.617

MNK1 and MNK2 regulation in HER2-overexpressing breast cancer lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.617

Regulation of sprouty stability by Mnk1-dependent phosphorylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.617

YB-1 evokes susceptibility to cancer through cytokinesis failure, mitotic dysfunction and HER2 amplification

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.617

The expression of activated Y-box binding protein-1 serine 102 mediates trastuzumab resistance in breast cancer cells by increasing CD44+ cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.617

Characterization of the cDNA encoding a protein binding to the major histocompatibility complex class II Y box

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.617

Epidermal growth factor receptor coexpression modulates susceptibility to Herceptin in HER2/neu overexpressing breast cancer cells via specific erbB-receptor interaction and activation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.617

Profiling YB-1 target genes uncovers a new mechanism for MET receptor regulation in normal and malignant human mammary cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.617

Targeting inhibitor of apoptosis proteins in combination with ErbB antagonists in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.617

MNK1, a new MAP kinase-activated protein kinase, isolated by a novel expression screening method for identifying protein kinase substrates

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.617

MAP kinase-interacting kinase 1 regulates SMAD2-dependent TGF-β signaling pathway in human glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.617

hnRNP A1 relocalization to the stress granules reflects a role in the stress response.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.617

Redefining prognostic factors for breast cancer: YB-1 is a stronger predictor of relapse and disease-specific survival than estrogen receptor or HER-2 across all tumor subtypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.617

Candidate genes for sensitivity and resistance of human glioblastoma multiforme cell lines to erlotinib. Laboratory investigation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.617

Serine 727 phosphorylation and activation of cytosolic phospholipase A2 by MNK1-related protein kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.617

Herceptin sensitizes ErbB2-overexpressing cells to apoptosis by reducing antiapoptotic Mcl-1 expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.617

beta -Arrestin-mediated recruitment of the Src family kinase Yes mediates endothelin-1-stimulated glucose transport

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.617

Confirming the RNAi-mediated mechanism of action of siRNA-based cancer therapeutics in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.617

Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.617

Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.617

Lapatinib resistance in HCT116 cells is mediated by elevated MCL-1 expression and decreased BAK activation and not by ERBB receptor kinase mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.617

PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.617

HER2 therapy: molecular mechanisms of trastuzumab resistance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.617

Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.617

Targeting RSK: an overview of small molecule inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.617

Human breast cancer cells selected for resistance to trastuzumab in vivo overexpress epidermal growth factor receptor and ErbB ligands and remain dependent on the ErbB receptor network

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.617

Met receptor contributes to trastuzumab resistance of Her2-overexpressing breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.617

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.617

Attenuation of proteasome-induced proteolysis in skeletal muscle by {beta}-hydroxy-{beta}-methylbutyrate in cancer-induced muscle loss

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.617

Y-box binding protein-1 serine 102 is a downstream target of p90 ribosomal S6 kinase in basal-like breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.617

Akt phosphorylates the Y-box binding protein 1 at Ser102 located in the cold shock domain and affects the anchorage-independent growth of breast cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.617

Y-box binding protein-1 induces the expression of CD44 and CD49f leading to enhanced self-renewal, mammosphere growth, and drug resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.617

Tamoxifen long-term treatment in vitro alters the apoptotic response of MCF-7 breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.617

Combined deficiency for MAP kinase-interacting kinase 1 and 2 (Mnk1 and Mnk2) delays tumor development

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.617

Mnk2 and Mnk1 are essential for constitutive and inducible phosphorylation of eukaryotic initiation factor 4E but not for cell growth or development

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.617

Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.617

Mitogen-activated protein kinases activate the serine/threonine kinases Mnk1 and Mnk2

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.617

Dissecting eIF4E action in tumorigenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.617

Disruption of the Y-box binding protein-1 results in suppression of the epidermal growth factor receptor and HER-2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.617

Combating trastuzumab resistance by targeting SRC, a common node downstream of multiple resistance pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.617

Elevation of receptor tyrosine kinase EphA2 mediates resistance to trastuzumab therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.617

The Mnks are novel components in the control of TNF alpha biosynthesis and phosphorylate and regulate hnRNP A1

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.617

Clinical significance of HER-2/neu oncogene amplification in primary breast cancer. The South Australian Breast Cancer Study Group

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2011.617

31 March 2020

Identifiers

DOI

10.1038/ONC.2011.617

1 reference

11 September 2017

1 reference